Jade Biosciences, Inc. (JBIO): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of JBIO were reported in the last 12 months. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Jade Biosciences
From the latest filingsOverall: more buying than selling. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns JBIO
152 funds and institutions reported JBIO shares worth $1.7B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 18.5%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 9.13M | 18.49% | $203M | +29% |
| Jupiter Topco LLC | 6.27M | 12.71% | $139M | – |
| Fairmount Funds Management LLC | 4.55M | 9.23% | $101M | No change |
| Ra Capital Management, L.P. | 3.67M | 7.44% | $81.6M | No change |
| Venrock Adviser, LLC | 3.22M | 6.52% | $71.6M | No change |
| Bellevue Group AG | 3.06M | 6.20% | $67.9M | -13% |
| Paradigm Biocapital Advisors LP | 2.86M | 5.79% | $63.5M | – |
| BlackRock, Inc. | 2.80M | 5.68% | $62.2M | +21% |
| Franklin Resources Inc | 2.79M | 5.66% | $62M | – |
| State Street Corp | 2.34M | 4.73% | $51.9M | +256% |
| Vanguard Capital Management LLC | 2.24M | 4.55% | $49.9M | +25% |
| Adage Capital Partners Gp, L.l.c. | 1.91M | 3.87% | $42.5M | – |
| Polar Capital Holdings Plc | 1.85M | 3.74% | $41M | – |
| Avidity Partners Management LP | 1.70M | 3.45% | $37.8M | -39% |
| Remedium Capital Partners, LLC | 1.58M | 3.20% | $35.1M | No change |
| Soleus Capital Management, L.P. | 1.55M | 3.14% | $34.5M | +95% |
| JPMorgan Chase & Co | 1.48M | 2.99% | $32.6M | – |
| Baker Bros. Advisors LP | 1.23M | 2.49% | $27.3M | -25% |
| Logos Global Management LP | 1.12M | 2.28% | $25M | +181% |
| California State Teachers Retirement System | 1.00M | 2.03% | $45.1M | +57707% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No JBIO insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
JBIO short interest
High short interest. 16.3% of JBIO shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 205%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 10.37M JBIO shares were sold short, 16.3% of the shares outstanding, down 7.5% from the report before. At the average daily volume of 735,575 shares, buying them all back would take about 14.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 10.37M | 16.31% | -7% | 735,575 | 14.1 |
| Oct 15, 2026 | 11.21M | 17.63% | -7% | 1.03M | 10.9 |
| Sep 30, 2026 | 12.12M | 19.06% | +10% | 1.07M | 11.3 |
| Sep 15, 2026 | 10.98M | 17.27% | +10% | 933,970 | 11.8 |
| Aug 31, 2026 | 9.99M | 15.72% | +4% | 606,567 | 16.5 |
| Aug 14, 2026 | 9.65M | 15.17% | +11% | 951,158 | 10.2 |
| Jul 31, 2026 | 8.69M | 17.61% | +15% | 755,922 | 11.5 |
| Jul 15, 2026 | 7.53M | 15.25% | -8% | 1.05M | 7.2 |
| Jun 30, 2026 | 8.15M | 16.51% | +65% | 1.68M | 4.8 |
| Jun 15, 2026 | 4.95M | 10.02% | +56% | 1.60M | 3.1 |
| May 29, 2026 | 3.16M | 6.41% | -7% | 582,751 | 5.4 |
| May 15, 2026 | 3.40M | 6.88% | +10% | 443,565 | 7.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Jade Biosciences company events
Jade Biosciences filed 13 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Sep 30, 2026.
- Sep 30, 2026AnnouncementJade Biosciences, Inc. announced preclinical data characterizing JADE301, its anti-interferon beta monoclonal antibody in development for dermatomyositis, a rare, chronic and debilitating autoimmune disease characterized by painful inflammatory skin disease and progressive muscle weakness. Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Jul 1, 2026AgreementJade Biosciences, Inc. entered into a License Agreement with Paragon Therapeutics, Inc., pursuant to which Paragon granted the Company a royalty-bearing, worldwide, exclusive and sublicensable license to use, make, sell, import, export and otherwise exploit certain monospecific antibodies and… Filing
- Jun 26, 2026LeadershipThe Board of Directors of Jade Biosciences, Inc. appointed Mark Eisner, M.D., M.P.H., to serve as a Class I director of the Company, to hold office until the Company’s 2028 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier resignation, death… Filing
- Jun 11, 2026VoteReported shareholder vote results. Filing
- Jun 4, 2026AnnouncementJade Biosciences, Inc. entered into an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC and UBS Securities LLC, as representatives of the several underwriters named therein, relating to the issuance and sale of 10,000,000 shares of the Company’s common stock, par value $0.0001 per… Filing
- Jun 1, 2026AnnouncementThe Company announced interim results from its Phase 1 healthy volunteer trial evaluating JADE101in development for the treatment of IgAN. JADE101 is designed with ultra-high binding affinity to selectively block APRIL, a key driver of pathogenic IgA production in IgAN, a chronic autoimmune disease… Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 22, 2026LeadershipThe Board of Directors of Jade Biosciences, Inc. appointed Andrew King, BVMS, Ph.D. as the Company’s President, Research & Development, effective as of April 18, 2026. Filing
- Apr 2, 2026LeadershipThe Board of Directors of Jade Biosciences, Inc. approved the Jade Biosciences, Inc. 2026 Employment Inducement Stock Incentive Plan. Filing
- Mar 6, 2026ResultsReleased financial results. Filing
- Jan 5, 2026ResultsReleased financial results. Filing
- Dec 15, 2025AgreementJade Biosciences, Inc. entered into a securities purchase agreement with the purchaser named therein, for the private placement of 3,214,286 shares of the Company’s common stock, par value $0.0001 per share, at a price of $14.00 per Share. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Jade Biosciences financials
Famous investors that hold JBIO
4 of the 50 well-known investors we track reported holding JBIO in their latest 13F filing. The largest position is Ken Griffin's, worth $13.1M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 929,291 | $13.1M | 0.0% | No change |
| Israel Englander · Millennium Management | Q3 2026 | 420,542 | $5.9M | 0.0% | +34% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 382,478 | $5.4M | 0.0% | +129% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 21,100 | $296K | 0.0% | -71% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 12 filings named JBIO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Bellevue Group AG | 13G/A | 6.8% |
| Nov 16, 2026 | Paradigm BioCapital Advisors LP | 13G/A | 9.5% |
| Nov 16, 2026 | Bellevue Group AG | 13G/A | 6.8% |
| Nov 16, 2026 | RA Capital Management, L.P. | 13G/A | 2.9% |
| Nov 16, 2026 | Venrock Healthcare Capital Partners III, L.P. | 13G/A | 5.9% |
| Nov 16, 2026 | Paradigm BioCapital Advisors LP | 13G/A | 9.5% |
| Nov 16, 2026 | RA Capital Management, L.P. | 13G/A | 2.9% |
| Nov 16, 2026 | Venrock Healthcare Capital Partners III, L.P. | 13G/A | 5.9% |
| Oct 28, 2026 | Franklin Templeton, Inc. | 13G | 6.0% |
| Oct 28, 2026 | Franklin Templeton, Inc. | 13G | 6.0% |
| Oct 27, 2026 | BlackRock, Inc. | 13G | 5.2% |
| Oct 27, 2026 | BlackRock, Inc. | 13G | 5.2% |
Questions about Jade Biosciences, Inc. (JBIO) stock
Who owns the most JBIO stock?
The largest reported owner of Jade Biosciences, Inc. (JBIO) is FMR LLC (Fidelity), with 18.5% of the company. In total, 152 funds and institutions reported holding JBIO at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are JBIO insiders buying or selling?
No JBIO insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in JBIO?
As of Oct 30, 2026, 10.37M JBIO shares were sold short, 16.3% of the shares outstanding, down 7.5% from the report before. At the average daily volume of 735,575 shares, buying them all back would take about 14.1 trading days (days to cover). See the history.
Which famous investors hold JBIO?
4 of the 50 well-known investors we track reported JBIO in their latest 13F filing, including Ken Griffin, Israel Englander, Steve Cohen. The largest position is worth $13.1M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.